Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The goal of this clinical trial is to learn which one works to treat better in patients with sudden sensorineural hearing loss, oral or intratympanic corticosteroid treatment. The main question it aims to answer is: Which corticosteroid treatment is more effective in patients with sudden sensorineural hearing loss, oral or intratympanic? * In our study, it was planned to divide the treatment schemes compared into two groups. Group 1 included patients who received oral methylprednisolone treatment daily for 2 weeks (48 mg for the first 7 days, 32 mg for the following 2 days, 16 mg for the 2 days, and 8 mg for the last 3 days). Group 2 included patients who received intratympanic 8 mg/2 ml dexamethasone every other day, totally 4 doses. * Visit the clinic after diagnose in first week, second week, first month and second month for checkups and tests ( temporal MR, odimetric results)

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• 18 years of age and older

• Unilateral sudden sensorineural hearing loss that developed within 72 hours and has lasted for 14 days or less

• Affected side PTA (500-100-2000-4000hz) should be over 50dB

• Affected side should be at least 30dB lower than healthy side in 3 frequencies

• Hearing should be symmetrical according to patient's statement before sensorineural hearing loss

• If used, steroid use should be less than 10 days

• Cerebellar and vestibular examination should be normal

Locations
Other Locations
Turkey
Dr Lütfi Kırdar City Hospital
RECRUITING
Istanbul
Contact Information
Primary
Koray Islek
islekkoray@gmail.com
+905380457016
Backup
Volkan Oztemel
Volkanoztemel508@gmail.com
+095396726250
Time Frame
Start Date: 2025-05-20
Estimated Completion Date: 2028-09-10
Participants
Target number of participants: 214
Treatments
Active_comparator: oral methylprednisolone treatment
Group 1 included patients who received oral methylprednisolone treatment daily for 2 weeks (48 mg for the first 7 days, 32 mg for the following 2 days, 16 mg for the 2 days, and 8 mg for the last 3 days).
Active_comparator: intratympanic dexamethasone treatment
Group 2 included patients who received intratympanic 8 mg/2 ml dexamethasone every other day, totally 4 doses.
Related Therapeutic Areas
Sponsors
Leads: Dr. Lutfi Kirdar Kartal Training and Research Hospital

This content was sourced from clinicaltrials.gov